EGFR and non-small cell lung carcinoma: Furthermore, EGFR-mutant NSCLC patients who developed resistance to EGFR-TKIs via acquisition of T790M showed lower tumor PD-L1 expression levels and also a lower proportion of patients with positive tumor PD-L1 expression [16,17].